Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

Author(s):
Witte, T. de; Suciu, S.; Meert, L.; Halkes, C.; Selleslag, D.; Bron, D.; Amadori, S.; Willemze, R. (0000-0001-9115-3106); Muus, P.; Baron, F.
Published
2015
Publication type
Article / Letter to editor
High-risk myelodysplastic syndromesSecondary acute myeloid leukemiaGemtuzumab ozogamicinChronic myelomonocytic leukemiaLiver toxicityCytogenetic risk score
Date issued
2015-12-31
Language
English
Is part of
Annals of Hematology (2015), Vol. 94, no. 12, p. 1981-1989
hdl
1887/106796
doi
10.1007/s00277-015-2486-9